Wockhardt's Antibiotic Zaynich Gets US FDA Approval for Complicated UTIs
Breakthrough Drug Targets Superbugs, Also Approved in India for UTIs and Bacteremia
L'essentiel
- Wockhardt's novel antibiotic Zaynich (cefepime and zidebactam) has received US FDA approval for treating complicated urinary tract infections (UTIs), including pyelonephritis, caused by resistant microorganisms.
- It also gained approval in India for UTIs and concurrent Gram-negative bacteremia, addressing the growing antimicrobial resistance threat.
Résumé généré par IA
Wockhardt's novel antibiotic Zaynich (cefepime and zidebactam) has received US FDA approval for treating complicated urinary tract infections (UTIs), including pyelonephritis, caused by resistant microorganisms. It also gained approval in India for UTIs and concurrent Gram-negative bacteremia, addressing the growing antimicrobial resistance threat.